Monogenic Obesity; Using Drugs to Bypass the Problem.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29972795.
- Also identified by DOI 10.1016/j.cmet.2018.06.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Safe and effective pharmacological treatments for severe obesity remain scarce. In this issue of Cell Metabolism, Iepsen et al. (2018) show that obese patients with pathogenic melanocortin 4 receptor mutations, the most common form of monogenic obesity, lose weight with glucagon-like peptide 1 (GLP-1) receptor agonist therapy.
Medical subject headings
- Obesity
- Receptor, Melanocortin, Type 4